Publications

Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.

* denotes publications from the CTD2 initiative that are results of intra-Network collaborations

 

CTD²
January 24, 2019
JCI Insight

Scientists at JHU showed that there is an intra-tumor and inter-patient heterogeneity to drug responses in patient-derived primary liver organoids. These studies indicate the potential use of pre-clinical organoid models in screening small-molecules and identifying novel targets.

CTD²
January 16, 2019
Nature Communications

OHSU CTD2 scientists identify distinct patterns of mutation dynamics during FLT3 inhibitor, crenolanib treatment in acute myeloid leukemia. This study indicates comprehensive sequencing should be carried before and during the treatment to identify combinatorial agents and prevent drug resistance.

CTD²
January 10, 2019
Cell

Study identifies networks of DNA damage-up proteins that may predict tumorigenic functions of cancer-promoting proteins.

CTD²
January 07, 2019
PLoS One

CTD2 researchers developed phospho-proteomic specific algorithm, pARACNe, which measures phospho-state dependencies between tyrosine kinases and their candidate substrates from large-scale LC-MS/MS phosphoproteomic profiles.

CGCI
January 07, 2019
Blood

Scientists from BLGSP demonstrated that tumor EBV status defines a specific BL phenotype irrespective of geographic origin with particular molecular properties and distinct pathogenic mechanisms. EBV-positive BL genomes feature fewer driver mutations despite their greater mutational load.

CTD²
January 01, 2019
Nature Medicine

UCSF (1) CTD2 researchers identified a synthetic lethal interaction between EGFR tyrosine kinase inhibitors and Aurora kinase inhibitors in acquired resistant cells. This study suggests combinatorial treatment to prevent treatment resistance with the monotherapies.

CTD²
December 26, 2018
Cell Systems

Bioinformatic approach, Similarity Weighted Nonnegative Embedding (SWNE), enables visualization of single-cell gene expression data into biologically relevant factors.

CTD²
December 24, 2018
OncoImmunology

UCSD study suggests that the combination of APOBEC-related mutagenesis and tumor mutation burden may be used as a biomarker of response to immunotherapy.

CTD²
December 21, 2018
Cancers

Analysis of next generation sequencing of patients with hematologic malignancies showed that patients had alterations that could be targeted with gene or immune-targeted therapies.

Pages

CSVXML